Selvita is a product and solution provider for the pharmaceutical and biotechnology industry from Krakow, Poland. We deliver comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at lowering the cost of introducing innovative compounds to the market. In cooperation with different laboratories we have initiated several projects from the area of oncology and central nervous system. All projects developed by our company are in the discovery and early preclinical phase. Our most advanced project, SEL24, involves a group of highly potent and selective compounds which are specific inhibitors of Pim-1 kinase, with IC50 at low nM concentration. These are potentially first in class specific Pim-1 inhibitors. SEL24 is currently in the lead optimization phase. First administration to humans is planned to take place in 2011. Selvita also actively explores the area of psychiatric disorders, with a current focus on the schizophrenia and cognitive diseases. Currently, we have an active pre-clinical development project, on a selective antagonist of 5-HT6 receptor, SEL73, which is being developed for indications such as Alzheimer’s disease or schizophrenia

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/23002 must be provided.

1. In vitro and in vivo evaluation of novel Pim kinase inhibitors with potent anticancer activity